Isabelle van Rycke

Amministratore Delegato presso Upsa Belgium SA

Distribution Services

Health Technology

Profilo

Ms. Isabelle van Rycke is a Chairman & Chief Executive Officer at UPSA SAS and a Co-Managing Director & Director at UPSA Belgium SA. She is on the Board of Directors at UPSA Belgium SA.

Posizioni attive di Isabelle van Rycke

Società	Posizione	Inizio
Upsa Belgium SA Upsa Belgium SA Medical DistributorsDistribution Services UPSA Belgium SA wholesales pharmaceutical products. The private company is based in Etterbeek, Belgium. The CEOs are Isabelle van Rycke, Jun Kuroda. The Belgian company was founded in 2019.	Amministratore Delegato	01/07/2021
UPSA SAS UPSA SAS Pharmaceuticals: MajorHealth Technology Part of Taisho Pharmaceutical Holdings Co., Ltd., UPSA SAS is a pharmaceutical laboratory that specializes in effervescence, pain treatment, ENT disorders, vitality, digestion, and sleep quality. The company is based in Rueil-Malmaison, France. The CEOs of the French company are Anthony Lallier and Isabelle van Rycke. UPSA was acquired by Taisho Pharmaceutical Co., Ltd. from Bristol Myers Squibb Co. on July 01, 2019 for $1,465.24 million.	Amministratore Delegato	01/05/2021

Tutte le posizioni attive di Isabelle van Rycke

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Isabelle van Rycke

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Upsa Belgium SA Upsa Belgium SA Medical DistributorsDistribution Services UPSA Belgium SA wholesales pharmaceutical products. The private company is based in Etterbeek, Belgium. The CEOs are Isabelle van Rycke, Jun Kuroda. The Belgian company was founded in 2019.	Distribution Services
UPSA SAS UPSA SAS Pharmaceuticals: MajorHealth Technology Part of Taisho Pharmaceutical Holdings Co., Ltd., UPSA SAS is a pharmaceutical laboratory that specializes in effervescence, pain treatment, ENT disorders, vitality, digestion, and sleep quality. The company is based in Rueil-Malmaison, France. The CEOs of the French company are Anthony Lallier and Isabelle van Rycke. UPSA was acquired by Taisho Pharmaceutical Co., Ltd. from Bristol Myers Squibb Co. on July 01, 2019 for $1,465.24 million.	Health Technology